TY  - GEN
AU  - Vuylsteke,P
AU  - Huizing,M
AU  - Petrakova,K
AU  - Roylance,R
AU  - Laing,R
AU  - Chan,S
AU  - Abell,F
AU  - Gendreau,S
AU  - Rooney,I
AU  - Apt,D
AU  - Zhou,J
AU  - Singel,S
AU  - Fehrenbacher,L
TI  - Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study
SN  - 1569-8041
PY  - 2017///1226
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Class I Phosphatidylinositol 3-Kinases
KW  - antagonists & inhibitors
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Indazoles
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Neoplasm Recurrence, Local
KW  - Paclitaxel
KW  - Receptor, ErbB-2
KW  - genetics
KW  - Sulfonamides
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdw320
ER  -